

UK INTERDISCIPLINARY BREAST CANCER SYMPOSIUM

15TH-16TH JANUARY 2018

MANCHESTER CENTRAL CONVENTION CENTRE

PROGRAMME AT A GLANCE

Updated 21/11/17

MONDAY 15TH JANUARY 2018

	AUDITORIUM	CHARTER 1	CHARTER 2 & 3	EXCHANGE HALL (EXHIBITION)
07.45 – 09.00				REGISTRATION TEA/COFFEE
09.00 – 09.10	Opening Professor Mitch Dowsett Baroness Delyth Morgan			
09.10 – 09.50	Highlights of 2017 (I) Chairs: <i>Dr Daniel Hayes</i> <i>Professor Arnie Purushotham</i> Basic research <i>Professor Clare Isacke</i> Translational research <i>Professor Peter Schmid</i>			
09.50-10.20	Key note lecture: Dr Laura Esserman Chair: <i>Miss Julie Doughty</i> Innovation in neoadjuvant chemotherapy			
10.20-11.00	Highlights of 2017 (II) Chairs: <i>Dr Daniel Hayes</i> <i>Professor Arnie Purushotham</i> Early Disease <i>Professor Michael Gnant</i> Late Disease <i>Dr Mark Verrill</i>			
11.00 – 11.25				TEA/COFFEE
11.25-11.30	Circulation between meeting rooms			
11.30 – 12.45	Metastatic Disease Chairs: <i>Professor Andrew Tutt</i>	Ductal Carcinoma In Situ Chairs: <i>Dr Tony Maxwell</i>	Model systems Chairs: <i>Professor Ingunn Holen</i>	

UK INTERDISCIPLINARY BREAST CANCER SYMPOSIUM

15TH-16TH JANUARY 2018

MANCHESTER CENTRAL CONVENTION CENTRE

	<p><i>Dr Catherine Harper-Wynne</i></p> <p>Managing ER+ Disease Professor Stephen Johnston Predicting outcome in metastatic breast cancer Dr Aleix Prat Evolution of resistance Professor Adrian Harris</p> <p>Selected Free Communication: RADICAL phase Ib/IIa study of AZD4547 combined with anastrozole or letrozole in AI resistant ER+ breast cancer patients <u>Dr Michael Seckl</u>, Imperial College London</p>	<p><i>Mr Mark Sibbering</i></p> <p>Avoiding overtreatment of DCIS Dr Judy Boughey How wide a margin do we need for DCIS? Professor Sarah Pinder Should radiotherapy be routinely recommended after wide local excision of DCIS? Professor David Dodwell</p> <p>Selected Free Communication: Does immediate breast reconstruction delay the delivery of adjuvant treatment? The iBRA-2 prospective multicentre cohort study <u>The Breast Reconstruction Research Collaborative</u></p>	<p><i>Professor Valerie Speirs</i></p> <p>The use of patient-derived tissues for advanced, preclinical models of breast cancer Dr Rob Clarke Organoid models Dr Mathew Garnett 3D in vitro modelling using material from Breast Cancer Now Tissue Bank Dr Richard Grose</p> <p>Selected Free Communication: Targeting IL1β-Wnt signalling prevents breast cancer colonisation in the bone microenvironment <u>Dr Rachel Eyre</u> University of Manchester, Manchester</p>	
12.45 – 13.55		12.50 – 13.50 Industry Symposia: Amgen	12.50 – 13.50 Industry Symposia: Roche	LUNCH
13.55 – 14.00 Circulation between meeting rooms				
14.00 – 14.30	<p>LeCure lecture: Dr Marc Lippman Chair: Professor Ian Smith Breast Cancer Research: Past and Future</p>			
14.30 – 14.35 Circulation between meeting rooms				
14.35 – 15.55	<p>Neoadjuvant therapy Chairs: Dr Andreas Makris Professor Ian Smith</p> <p>Neoadjuvant therapy as a surgical tool Professor Mike Dixon</p>	<p>Image analysis for scientists and pathologists Chairs: Professor Tony Ng Professor Sarah Pinder</p> <p>Applying digital pathology to translational breast cancer research Professor Valerie Speirs</p>	<p>Workshop: A practical guide to shared decision making: Putting research into practice Chairs: Professor Deborah Fenlon Mrs Lesley Turner</p> <p>The benefits of shared decision making Professor Diana Harcourt</p>	

UK INTERDISCIPLINARY BREAST CANCER SYMPOSIUM

15TH-16TH JANUARY 2018

MANCHESTER CENTRAL CONVENTION CENTRE

	<p>Treatment of the axilla post neoadjuvant chemotherapy Dr Judy Boughey <i>Neera Patel Lecture:</i> RCB vs pCR as an end-point Dr Fraser Symmans Imaging end-points for neoadjuvant therapy Dr Sarah Vinnicombe</p>	<p>Imaging-based analysis of ErbB/HER signaling dimer and immunoregulatory molecules – from preclinical science to biomarker discovery Professor Tony Ng Deciphering spatial heterogeneity of tumour immune response Dr Yinyin Yuan</p> <p>Selected Free Communication: Clinicopathological Significance of Heterogeneity of Tumour Infiltrating Lymphocytes in Invasive Breast Cancer Maryam Althobiti, University of Nottingham</p>	<p>What can help to help make a good decision in a difficult situation like breast cancer? Professor Alex Clarke Tools available to support shared decision making about breast reconstruction Dr Nicole Paraskeva</p>	
15.55 – 16.20				TEA/COFFEE
<p>16.20 – 16.25 Circulation between meeting rooms</p>				
16.25 – 17.40	<p>Selected Free Communication: <i>Chairs:</i> Professor Ian Ellis Mr Mark Sibbering</p> <p>Peri-operative Aromatase Inhibitor treatment in determining or predicting Longterm Outcome in Early Breast Cancer –the POETIC* Trial (CRUK/07/015) Professor Ian Smith, Royal Marsden Hospital, London</p> <p>Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces breast cancer recurrence and</p>	<p>Triple Negative Breast Cancer <i>Chairs:</i> Professor Andrew Tutt Professor Ingunn Holen</p> <p>The biology of new targets Professor Andrew Tutt Precision Medicine for Triple Negative Breast Cancer Patients Using a Systems Biology Approach Dr Chuck Perou Immunologic advances Professor Giuseppe Curigliano</p> <p>Selected Free Communication:</p>	<p>Costs of treatment <i>Chairs:</i> Professor Arnie Purushotham Mrs Ursula Van Mann</p> <p>From price to value: Keeping breast cancer care affordable Professor Richard Sullivan Critically examining the true value of our therapies: The only way to meaningful gains in breast cancer Professor Tito Fojo</p>	

UK INTERDISCIPLINARY BREAST CANCER SYMPOSIUM

15TH-16TH JANUARY 2018

MANCHESTER CENTRAL CONVENTION CENTRE

	<p>mortality: an EBCTCG meta-analysis of 34,123 women in 25 randomised trials. <u>Dr Richard Gray</u>, University of Oxford</p> <p>Integration of clinical variables for the prediction of late distant recurrence in patients with oestrogen receptor positive breast cancer treated with 5 years of endocrine therapy <u>Dr Ivana Sestak</u>, Centre for Cancer Prevention, Queen Mary University London</p> <p>A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT – Randomised EuropeAn Celecoxib Trial) Professor RC Coombes, Imperial College, London</p> <p>Impact of a BRCA germline mutation on survival - Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH) <u>Professor Diana Eccles</u>, University of Southampton</p>	<p>Comprehensive molecular characterisation of TNBCs expressing <i>HORMAD1</i>, a driver of homologous recombination deficiency <u>Jelmar Quist</u>, King's College London</p>		
<p>17.40 – 17.45 Circulation between meeting rooms</p>				
<p>17.45 – 18.15</p>	<p>Key note lecture: Professor Sir David Spiegelhalter Chair: Professor Dame Lesley Fallowfield Understanding Risk</p>			
<p>18.15 – 19.15</p>				<p>DRINKS RECEPTION AND POSTER VIEWING</p>

UK INTERDISCIPLINARY BREAST CANCER SYMPOSIUM

15TH-16TH JANUARY 2018

MANCHESTER CENTRAL CONVENTION CENTRE

TUESDAY 16TH JANUARY 2018

	AUDITORIUM	CHARTER 1	CHARTER 2 & 3	EXCHANGE HALL (EXHIBITION)
07.50 – 08.50		Industry Symposia: Daiichi-Sankyo	Industry Symposia: Novartis	TEA/COFFEE & POSTER JUDGING
09.00 – 09.30	Key note lecture sponsored by BACR: Professor Jack Cuzick Chair: Professor Gareth Evans Breast cancer prevention for the population at large			
09.30 – 09.35 Circulation between meeting rooms				
09.35 – 10.55	Measuring and managing breast cancer risk Chairs: Dr Tony Maxwell Ms Christine Lee-Jones Stratification of screening Professor Fiona Gilbert Risk prediction for risk reduction Professor Gareth Evans Findings from the Generations study Professor Anthony Swerdlow Identifying genetic risk in the prevalent breast cancer population Professor Nazneen Rahman	Novel Clinical Trial End-points Chairs: Professor Judith Bliss Dr Nick Turner Why do we need better trial end-points? Professor Judith Bliss Novel trial endpoints: Opportunities & challenges for new surrogate endpoints Dr Marc Buyse	Breast Cancer Heterogeneity and Evolution Chairs: Professor Stephen Johnston Professor Carlos Caldos Genomic Heterogeneity of Breast Cancer Dr Lucy Yates Experimental modelling of heterogeneity Dr Rachael Natrajan Relevance to the histopathologist Dr Fraser Symmans Selected Free Communication: Comparative transcriptomic analysis of long-term neoadjuvant letrozole-treated dormant and acquired resistant tumours using sequential clinical samples Cigdem Selli, Edinburgh	
10.55 – 11.20				TEA/COFFEE

UK INTERDISCIPLINARY BREAST CANCER SYMPOSIUM

15TH-16TH JANUARY 2018

MANCHESTER CENTRAL CONVENTION CENTRE

11.20-11.25					Circulation between meeting rooms				
11.25 – 12.45	New treatments and measuring their impact Chairs: <i>Dr Julia Gee</i> <i>Professor Adrian Harris</i> CDK4/6 inhibition Dr Nick Turner New Selective Oestrogen Receptor Downregulators (SERDS) Dr Lesley-Ann Martin Liquid biopsies Professor Jacqui Shaw Selected Free Communication: Finding determinants of PARP inhibitor sensitivity using genome-wide and focused CRISPR screens <u>Stephen Pettitt</u> , Institute of Cancer Research, London		Lobular breast cancer Chair: <i>Professor David Dodwell</i> <i>Dr Adrienne Morgan</i> Unique biology in invasive lobular breast cancer Professor Steffi Oesterreich Genetic aspects Professor Elinor Sawyer Histologic dilemmas Professor Ian Ellis Should lobular phenotype be considered when deciding treatment? Professor Michael Kerin		Communicating risk in the context of genomic testing Chairs: <i>Professor Sir David Spiegelhalter</i> <i>Professor Dame Lesley Fallowfield</i> Communicating the potential benefits and harms of medical interventions <i>Professor Sir David Spiegelhalter</i>				
12.45 – 13.55			12.50 – 13.50 Industry Symposia: Amgen		12.50 – 13.50 Industry symposia: Nanostring Prosigna in Context: Clinical Evidence and Comparative Performance with other Multi-Parameter Tests Perspective and experience of clinical implications of breast cancer molecular subtype Dr Aleix Prat Prosigna data and beyond: Comparison of genomic tests Dr Ivana Sestak Prosigna in the UK: OPTIMA trial, and other perspectives Dr Andreas Makris		LUNCH		
13.55 – 14.00					Circulation between meeting rooms				
14.00 – 14.30	Cridlan lecture: Dr Chuck Perou Chair: <i>Dr Gill Ross</i> Completion of the Cancer Genome Atlas								

UK INTERDISCIPLINARY BREAST CANCER SYMPOSIUM

15TH-16TH JANUARY 2018

MANCHESTER CENTRAL CONVENTION CENTRE

14.30 – 14.35 Circulation between meeting rooms				
14.35– 15.55	<p>Biomarkers and prognostic profiling <i>Chairs:</i> Professor Mitch Dowsett Dr Fraser Symmans</p> <p>Lessons from molecular subtyping Professor Carlos Caldas</p> <p>Clinical utility of molecular profiles Professor Rob Stein</p> <p>Who needs extended endocrine therapy? Dr Daniel Hayes</p> <p>Mutation-directed therapy Professor Fabrice André</p>	<p>Challenges of local management <i>Chairs:</i> Miss Julie Doughty Dr Catherine Harper-Wynne</p> <p>Management and follow up of patients presenting with breast cancer in axillary lymph nodes and occult breast primary Dr Andreas Makris</p> <p>When is local surgery indicated in metastatic breast cancer? Miss Nicola Roche</p> <p>What is the impact of MRI scanning on breast cancer treatment? Professor Ulrich Bick</p> <p>Current and future indications for partial breast radiotherapy Dr Charlotte Coles</p>	<p>Clinical Trials Roadshow, chaired by Professor Daniel Rea</p> <p>Selected Free Communication: The LORIS Trial: Randomising patients with low or low intermediate grade Ductal Carcinoma In Situ (DCIS) to surgery or active monitoring. <u>Matthew Wallis</u>, Addenbrooke's Hospital, Cambridge</p> <p>Selected Free Communication: The plasmaMATCH Trial: A multiple parallel cohort, open-label, multi-centre phase II clinical trial of ctDNA screening to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010) <u>Nicholas Turner</u>, The Institute of Cancer Research, London</p> <p><i>Other selected trials to be confirmed</i></p>	
15.55 – 16.00 Circulation between meeting rooms				
16.00 – 16.10	Prize presentations			
16.10 – 16.40	<p>Key note lecture: Professor David Cameron <i>Chair:</i> Baroness Delyth Morgan Achievements of Breast Cancer Research in the UK</p>			
16.40	CLOSING REMARKS Professor Mitch Dowsett			
16.45	CLOSE OF MEETING			